EpiCept Corporation
http://www.epicept.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From EpiCept Corporation
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout
Plus deals involving Immunis/Toray, AstraZeneca/Nona, Swixx/Biopas, Deimos/G1, Serum Institute of India/IntegriMedical/ImmunityBio plus tech transfer agreements and deals in brief.
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits.
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.
Company Information
- Other Names / Subsidiaries
-
- Maxim Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice